- Home
- EWCZ vs GLSI Comparison
EWCZ vs GLSI Comparison
Compare EWCZ & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- GLSI
- Stock Information
- Founded
- EWCZ 2004
- GLSI 2006
- Country
- EWCZ United States
- GLSI United States
- Employees
- EWCZ N/A
- GLSI N/A
- Industry
- EWCZ Package Goods/Cosmetics
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- GLSI Health Care
- Exchange
- EWCZ Nasdaq
- GLSI Nasdaq
- Market Cap
- EWCZ 166.5M
- GLSI 145.2M
- IPO Year
- EWCZ 2021
- GLSI 2020
- Fundamental
- Price
- EWCZ $3.72
- GLSI $8.47
- Analyst Decision
- EWCZ Hold
- GLSI Strong Buy
- Analyst Count
- EWCZ 6
- GLSI 1
- Target Price
- EWCZ $5.50
- GLSI $39.00
- AVG Volume (30 Days)
- EWCZ 297.3K
- GLSI 80.5K
- Earning Date
- EWCZ 11-12-2025
- GLSI 11-14-2025
- Dividend Yield
- EWCZ N/A
- GLSI N/A
- EPS Growth
- EWCZ N/A
- GLSI N/A
- EPS
- EWCZ 0.20
- GLSI N/A
- Revenue
- EWCZ $212,509,000.00
- GLSI N/A
- Revenue This Year
- EWCZ N/A
- GLSI N/A
- Revenue Next Year
- EWCZ $2.27
- GLSI N/A
- P/E Ratio
- EWCZ $18.95
- GLSI N/A
- Revenue Growth
- EWCZ N/A
- GLSI N/A
- 52 Week Low
- EWCZ $2.72
- GLSI $8.01
- 52 Week High
- EWCZ $8.91
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- EWCZ 46.19
- GLSI 34.22
- Support Level
- EWCZ $3.47
- GLSI $8.02
- Resistance Level
- EWCZ $3.91
- GLSI $9.51
- Average True Range (ATR)
- EWCZ 0.16
- GLSI 0.52
- MACD
- EWCZ 0.03
- GLSI -0.08
- Stochastic Oscillator
- EWCZ 38.95
- GLSI 20.50
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.